(PDF) Liver Fibrosis Treatment Market Is Expected to Reach US$ 28 Billion at a 10.8% CAGR By 2026 | Future Growth Insights, Share Value, Top Key Players and Industry Dynamics

Global Liver Fibrosis Treatment Market
The Global Liver Fibrosis Treatment Market, segmented by End User (Specialty Clinics, Hospitals, and Others), By Treatment Type (Hepatotropic Drug, PPAR (Peroxisome Proliferator-activated Receptors) alpha agonist, and ACE Inhibitors), by Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa), and by Condition (Nonalcoholic Steatohepatitis, Chronic Liver Diseases, and Hepatitis C) is forecast to grow at a CAGR of 10.8 percent during the forecast period.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2320

Drivers

The global liver fibrosis treatment market is forecast to rise in the near future due to an increase in the number of clinical studies conducted by major companies aimed at developing an effective treatment option for liver fibrosis. FibroGen, Inc. began a phase II clinical trial of FG-3019, a human monoclonal antibody against the Connective Tissue Growth Factor (CTGF), in October 2010 to examine the efficacy in restoring the consequences of liver fibrosis induced by chronic hepatitis B virus infection (HBV). Intercept Pharmaceuticals, Inc. started the REVERSE study in phase III in February 2018. The effectiveness and safety of obeticholic acid in NASH patients with a biopsy-confirmed indication of cirrhotic will be evaluated in this randomized phase III research.

Competitive Landscape -

Key companies contributing in the global liver fibrosis treatment market are Johnson and Johnson, Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb, Merck & Co., Inc., Gilead Sciences, Inc., Pharmaxis Limited, FibroGen, Inc., Pfizer Inc., and Novartis AG.

“Limited Time Offer”

Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2320

In addition, rising research partnership among major companies to create innovative treatment regimes, as well as regulatory approval of new medications for the treatment of liver fibrosis, are projected to fuel the global liver fibrosis treatment market expansion in the near future. Nordic Bioscience and Bristol-Myers Squibb Company inked a partnership agreement in April 2017 to develop biomarker technologies that might be used to track and measure fibrosis diseases such as non-alcoholic steatohepatitis (NASH). This partnership will aid patients in diagnosing and monitoring their fibrosis. SYMDEKO was authorized by the Food and Drug Administration (FDA) in February 2018 for the therapy of CF (cystic fibrosis) in patients aged 12 and older with specific mutations.

Browse 24 Market Data Tables and 28 Figures spread through 168 Pages and in-depth TOC on ‘Liver Fibrosis Treatment Market, by End User (Specialty Clinics, Hospitals, and Others), by Treatment Type (Hepatotropic Drug, PPAR (Peroxisome Proliferator-activated Receptors) alpha agonist, and ACE Inhibitors), by Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa), and by Condition (Nonalcoholic Steatohepatitis, Chronic Liver Diseases, and Hepatitis C) - Global Forecast to 2026’

To understand Research Methodology, please click - https://www.coherentmarketinsights.com/market-insight/liver-fibrosis-treatment-market-2320

Key Takeaways

Due to the rising frequency of risk factors impacting liver fibrosis globally, the global liver fibrosis treatment market is projected to increase at a 10.8 percent CAGR during the forecast period.
Hepatotropic drugs accounted for a considerable market share in the liver fibrosis therapy industry, as they enable patients to get safe and effective treatment for fibrosis reduction.
Hospitals are anticipated to account for the majority of market share among end-users during the forecast period since clinics are the leading alternative for patients with liver fibrosis.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/liver-fibrosis-treatment-market-to-surpass-us-28-billion-by-2026-1197

Table of Content

Global Liver Fibrosis Treatment Market Research Report
Section 1: Global Liver Fibrosis Treatment Industry Overview
Section 2: Global Economic Impact on Liver Fibrosis Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Liver Fibrosis Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Liver Fibrosis Treatment Market Forecast

Other Related Reports:

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market - https://www.pharmiweb.com/press-release/2021-06-15/tumor-necrosis-factor-tnf-inhibitor-drugs-market-autoimmune-disease-treatments-detailed-study-by-coherent-market-insights-with-upcoming-trends

Plasma Protease C1-inhibitor Treatment Market - https://www.pharmiweb.com/press-release/2021-06-15/plasma-protease-c1-inhibitor-treatment-preclinical-safety-aspects-on-the-potential-prothrombotic-risk-market-will-grow-at-182-cagr-to-be-valued

Global Cancer Cell Market - https://www.pharmiweb.com/press-release/2021-06-15/cancer-cell-fasting-as-a-treatment-for-cancer-market-size-is-anticipated-to-reach-us-14-8035-million-at-a-cagr-of-820-by-2027

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

This release was published on openPR.